ReviewHematology. American Society of Hematology. Education Program2016
Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions.
Review in Hematology. American Society of Hematology. Education Program, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05762874 (Safety and Effectiveness of Ruxolitinib in Patients With Myelofibrosis), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Effectiveness of Ruxolitinib in Patients With Myelofibrosis
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Comprehensive High-Sensitivity Mutation Profiling in MPNs: Diagnostic and Prognostic Implications.Cancers · 2026Article
- The Immunological Consequences of Clonal Hematopoiesis in Heart Failure.Immunological reviews · 2026Review
- Mutational landscape of classical myeloproliferative neoplasms in the Western Cape Province, South Africa.African journal of laboratory medicine · 2026Article
- Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms.Translational oncology · 2025Article
- Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis.Annals of hematology · 2025Article
- Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis.JCI insight · 2024Article
- Article
- Article
- Clinical Impact ofTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- Clonal hematopoiesis, somatic mosaicism, and age-associated disease.Physiological reviews · 2023Review
- The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.Frontiers in oncology · 2023Article
- Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events.Blood advances · 2021Article
- Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway.Molecules (Basel, Switzerland) · 2021Article
- Disease modifying agents of myeloproliferative neoplasms: a review.Blood research · 2021Review
- Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.Pediatric blood & cancer · 2021Article
- Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms.Oncology letters · 2021Article
- Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding.Cancers · 2020Review
- Management of myelofibrosis after ruxolitinib failure.Annals of hematology · 2020Review
- Genetics of age-related clonal hematopoiesis and atherosclerotic cardiovascular disease.Current opinion in cardiology · 2020Review
- Cardiovascular Disease, Aging, and Clonal Hematopoiesis.Annual review of pathology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The last decade has witnessed tremendous scientific advances, ushered in by the JAK2 V617F discovery, contributing to enhanced diagnostic capability and understanding of the biology of myeloproliferative neoplasms (MPNs). Discovery of the calreticulin mutations filled a diagnostic gap; more recent work sheds light on its contribution to disease pathogenesis, and prognosis. Recent studies have also identified novel JAK2 and MPL mutations in patients with essential thrombocythemia and myelofibrosis (MF). Especially in MF, the driver mutational profile has prognostic implications, with additive contributions from the acquisition of additional somatic mutations. The hope is that sophisticated molecular profiling will not only aid in prognostication, but also guide selection of therapy for patients with MPNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.